

PUBLISHER CORRECTION

Open Access



CrossMark

# Publisher Correction: Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients

BMC Nephrology

## Erratum

In the original publication of this article [1], Table 3 is incorrect, several cell values in column 4 (no ESA ( $n = 8$ )) have been incorrectly shifted during typesetting.

In this Erratum the correct and incorrect version of Table 3 are published.

The publisher apologizes for the inconvenience caused by this error to the authors and readers.

Received: 18 September 2017 Accepted: 18 September 2017

Published online: 04 October 2017

## Reference

1. Bataille, et al. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients. *BMC Nephrol.* 2017;18:251. doi: 10.1186/s12882-017-0668-5.

\* Correspondence: info@biomedcentral.com  
London, UK

**Table 1** Incorrect version of Table 3 as published on 26 July 2017. The incorrect cells are displayed in *italics*

	Hb >10 g/dL			Hb ≤10 g/dL			<i>p</i> -value
	no ESA (n = 63)	ESA ≤40 µg/w (n = 75)	ESA >40 µg/w (n = 41)	no ESA (n = 8)	ESA ≤40 µg/w (n = 25)	ESA >40 µg/w (n = 28)	
Age (years)	67.8 ± 15.3	67.1 ± 16.2	69.9 ± 15.4	74.5 ± 8.1	64.8 ± 17.6	65.9 ± 18.3	0.63
Gender (male)	61.9%	58.7%	41.5%	62.5%	64.0%	42.9%	0.19
Diabetes	44.4%	41.3%	43.9%	37.5%	48.0%	35.7%	0.96
Hemoglobin (g/dL)	11.6 ± 0.9	11.2 ± 0.8	11.1 ± 0.8	9.6 ± 0.6	9.5 ± 0.4	9.0 ± 0.9	<0.001
TSAT (%)	29.2 ± 13.5	23.5 ± 9.2	22.7 ± 11.1	45.8 ± 27.4	25.6 ± 9.8	20.1 ± 17.4	<0.001
Ferritin (ng/mL)	480 ± 330	426 ± 285	473 ± 304	<i>1341 ± 1541</i>	636 ± 314	677 ± 901	<0.001
Albumin (g/L)	38.4 ± 4.4	39.2 ± 4.1	37.5 ± 4.8		37.8 ± 4.6	33.0 ± 7.8	<0.001
β2 microglobulin (mg/L)	26.2 ± 7.0	25.7 ± 6.9	27.4 ± 8.2	<i>34.1 ± 6.4</i>	25.6 ± 6.2	27.4 ± 7.0	0.008
Parathormone (pg/mL)	268 ± 318	284 ± 315	195 ± 207	<i>35.8 ± 9.8</i>	264 ± 354	237 ± 438	0.83
Predialysis creatinine (µmol/L)	764 ± 282	769 ± 242	684 ± 250	<i>224 ± 299</i>	757 ± 220	638 ± 239	0.08
Predialysis urea (mmol/L)	20.8 ± 5.9	21.7 ± 6.7	20.0 ± 6.5	<i>623 ± 153</i>	21.0 ± 6.1	19.6 ± 8.3	0.39
C-reactive protein (mg/L)	12.2 ± 18.9	12.7 ± 28.4	26.0 ± 67.4	<i>17.2 ± 5.5</i>	23.1 ± 49.9	36.5 ± 37.1	0.02
IAA (µmol/L)	5.10 ± 5.28	5.73 ± 5.97	3.51 ± 3.50	<i>51.9 ± 97.3</i>	4.67 ± 3.05	3.78 ± 2.60	0.09
IS (µmol/L)	92.8 ± 54.7	97.9 ± 45.2	100.9 ± 49.9	<i>2.29 ± 1.30</i>	85.2 ± 55.5	82.3 ± 61.9	0.54
PCS(µmol/L)	169 ± 101	172 ± 94	150 ± 97	<i>78.1 ± 37.6</i>	175 ± 98	96 ± 99	0.01
Iron medication							
IV iron medication	54.0%	68.0%	73.2%	<i>135 ± 75</i>	48.0%	64.3%	0.10
Iron dose (mg/mo)	175 ± 188	228 ± 245	351 ± 318	<i>163 ± 292</i>	124 ± 167	314 ± 374	0.002
HDF (%)	54.0%	30.7%	31.7%	50.0%	52.0%	46.4%	0.05
Kt/V	1.51 ± 0.26	1.50 ± 0.28	1.50 ± 0.42	<i>1.46 ± 0.30</i>	1.57 ± 0.26	1.51 ± 0.34	0.95

**Table 2** Correct version of Table 3, the corrected cells are displayed in **bold**

	Hb >10 g/dL			Hb ≤10 g/dL			<i>p</i> -value
	no ESA (n = 63)	ESA ≤40 µg/w (n = 75)	ESA >40 µg/w (n = 41)	no ESA (n = 8)	ESA ≤40 µg/w (n = 25)	ESA >40 µg/w (n = 28)	
Age (years)	67.8 ± 15.3	67.1 ± 16.2	69.9 ± 15.4	74.5 ± 8.1	64.8 ± 17.6	65.9 ± 18.3	0.63
Gender (male)	61.9%	58.7%	41.5%	62.5%	64.0%	42.9%	0.19
Diabetes	44.4%	41.3%	43.9%	37.5%	48.0%	35.7%	0.96
Hemoglobin (g/dL)	11.6 ± 0.9	11.2 ± 0.8	11.1 ± 0.8	9.6 ± 0.6	9.5 ± 0.4	9.0 ± 0.9	<0.001
TSAT (%)	29.2 ± 13.5	23.5 ± 9.2	22.7 ± 11.1	45.8 ± 27.4	25.6 ± 9.8	20.1 ± 17.4	<0.001
Ferritin (ng/mL)	480 ± 330	426 ± 285	473 ± 304	<b>1341 ± 1541</b>	636 ± 314	677 ± 901	<0.001
Albumin (g/L)	38.4 ± 4.4	39.2 ± 4.1	37.5 ± 4.8	<b>34.1 ± 6.4</b>	37.8 ± 4.6	33.0 ± 7.8	<0.001
β2 microglobulin (mg/L)	26.2 ± 7.0	25.7 ± 6.9	27.4 ± 8.2	<b>35.8 ± 9.8</b>	25.6 ± 6.2	27.4 ± 7.0	0.008
Parathormone (pg/mL)	268 ± 318	284 ± 315	195 ± 207	<b>224 ± 299</b>	264 ± 354	237 ± 438	0.83
Predialysis creatinine (µmol/L)	764 ± 282	769 ± 242	684 ± 250	<b>623 ± 153</b>	757 ± 220	638 ± 239	0.08
Predialysis urea (mmol/L)	20.8 ± 5.9	21.7 ± 6.7	20.0 ± 6.5	<b>17.2 ± 5.5</b>	21.0 ± 6.1	19.6 ± 8.3	0.39
C-reactive protein (mg/L)	12.2 ± 18.9	12.7 ± 28.4	26.0 ± 67.4	<b>51.9 ± 97.3</b>	23.1 ± 49.9	36.5 ± 37.1	0.02
IAA (µmol/L)	5.10 ± 5.28	5.73 ± 5.97	3.51 ± 3.50	<b>2.29 ± 1.30</b>	4.67 ± 3.05	3.78 ± 2.60	0.09
IS (µmol/L)	92.8 ± 54.7	97.9 ± 45.2	100.9 ± 49.9	<b>78.1 ± 37.6</b>	85.2 ± 55.5	82.3 ± 61.9	0.54
PCS(µmol/L)	169 ± 101	172 ± 94	150 ± 97	<b>135 ± 75</b>	175 ± 98	96 ± 99	0.01
Iron medication							
IV iron medication	54.0%	68.0%	73.2%	<b>37.5%</b>	48.0%	64.3%	0.10
Iron dose (mg/mo)	175 ± 188	228 ± 245	351 ± 318	163 ± 292	124 ± 167	314 ± 374	0.002
HDF (%)	54.0%	30.7%	31.7%	50.0%	52.0%	46.4%	0.05
Kt/V	1.51 ± 0.26	1.50 ± 0.28	1.50 ± 0.42	1.46 ± 0.30	1.57 ± 0.26	1.51 ± 0.34	0.95